Repeat expansion diseases: When a good RNA turns bad

Wiley Interdisciplinary Reviews: RNA

Volumn 1, Issue 1, 2010, Pages 173-192

  Dickson, Alexa M ^a   Wilusz, Carol J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; RNA BINDING PROTEIN; REPETITIVE DNA;

CELLULAR DISTRIBUTION; GENE EXPRESSION; GENETIC DISORDER; HUMAN; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REPEAT EXPANSION DISEASE; REVIEW; RNA INTERFERENCE; TOXICITY; ANIMAL; BIOLOGICAL MODEL; DISEASES; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; METHODOLOGY; MUTATION; PHYSIOLOGY; PROTEIN SYNTHESIS; REGULATORY RNA SEQUENCE;

ANIMALS; DISEASE; DNA REPEAT EXPANSION; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; MODELS, BIOLOGICAL; MUTATION; PROTEIN BIOSYNTHESIS; REGULATORY SEQUENCES, RIBONUCLEIC ACID; RNA;

EID: 84857740318     PISSN: 17577004     EISSN: 17577012     Source Type: Journal    
DOI: 10.1002/wrna.18     Document Type: Review

References (132)

1. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3 end of a transcript encoding a protein kinase family member. Cell 1992, 68: 799-808.
2. Howeler CJ, Busch HF, Geraedts JP, Niermeijer MF, Staal A. Anticipation in myotonic dystrophy: fact or fiction? Brain 1989, 112: 779-797.
3. Arocena DG, Iwahashi CK, Won N, Beilina A, Ludwig AL, et al. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet 2005, 14: 3661-3671.
4. Taneja KL. Localization of trinucleotide repeat sequences in myotonic dystrophy cells using a single fluorochrome-labeled PNA probe. Biotechniques 1998, 24: 472-476.
5. Rudnicki DD, Holmes SE, Lin MW, Thornton CA, Ross CA, et al. Huntington's disease-like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol 2007, 61: 272-282.
6. Lin X, Ashizawa T. SCA10 and ATTCT repeat expansion: clinical features and molecular aspects. Cytogenet Genome Res 2003, 100: 184-188.
7. Mankodi A, Teng-Umnuay P, Krym M, Henderson D, Swanson M, et al. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol 2003, 54: 760-768.
8. Daughters RS, Tuttle DL, Gao W, Ikeda Y, Moseley ML, et al. RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet 2009, 5: e1000600.
9. Lee JE, Cooper TA. Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans 2009, 37: 1281-1286.
10. Li LB, Yu Z, Teng X, Bonini NM. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 2008, 453: 1107-1111.
11. Mutsuddi M, Marshall CM, Benzow KA, Koob MD, Rebay I. The spinocerebellar ataxia 8 noncoding RNA causes neurodegeneration and associates with staufen in Drosophila. Curr Biol 2004, 14: 302-308.
12. Chen IC, Lin HY, Lee GC, Kao SH, Chen CM, et al. Spinocerebellar ataxia type 8 larger triplet expansion alters histone modification and induces RNA foci. BMC Mol Biol 2009, 10: 9.
13. Sato N, Amino T, Kobayashi K, Asakawa S, Ishiguro T, et al. Spinocerebellar ataxia type 31 is associated with "inserted" penta-nucleotide repeats containing (TGGAA)n. Am J Hum Genet 2009, 85: 544-557.
14. Handa V, Goldwater D, Stiles D, Cam M, Poy G, et al. Long CGG-repeat tracts are toxic to human cells: implications for carriers of Fragile X premutation alleles. FEBS Lett 2005, 579: 2702-2708.
15. Iwahashi CK, Yasui DH, An HJ, Greco CM, Tassone F, et al. Protein composition of the intranuclear inclusions of FXTAS. Brain 2006, 129: 256-271.
16. Hashem V, Galloway JN, Mori M, Willemsen R, Oostra BA, et al. Ectopic expression of CGG containing mRNA is neurotoxic in mammals. Hum Mol Genet 2009, 18: 2443-2451.
17. Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol 2008, 21: 497-503.
18. Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 1994, 6: 9-13.
19. Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 1996, 14: 277-284.
20. Yu Z, Wang AM, Robins DM, Lieberman AP. Altered RNA splicing contributes to skeletal muscle pathology in Kennedy disease knock-in mice. Dis Model Mech 2009, 2: 500-507.
21. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 1997, 15: 62-69.
22. Garden GA, La Spada AR. Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration. Cerebellum 2008, 7: 138-149.
23. Holmes SE, O'Hearn E, Margolis RL. Why is SCA12 different from other SCAs? Cytogenet Genome Res 2003, 100: 189-197.
24. Stevanin G, Brice A. Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4). Cerebellum 2008, 7: 170-178.
25. Bauer PO, Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem 2009, 110: 1737-1765.
26. Taneja KL, McCurrach M, Schalling M, Housman D, Singer RH. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol 1995, 128: 995-1002.
27. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001, 293: 864-867.
28. Napierala M, Krzyzosiak WJ. CUG repeats present in myotonin kinase RNA form metastable "slippery" hairpins. J Biol Chem 1997, 272: 31079-31085.
29. Sobczak K, Krzyzosiak WJ. CAG repeats containing CAA interruptions form branched hairpin structures in spinocerebellar ataxia type 2 transcripts. J Biol Chem 2005, 280: 3898-3910.
30. Napierala M, Michalowski D, de Mezer M, Krzyzosiak WJ. Facile FMR1 mRNA structure regulation by interruptions in CGG repeats. Nucleic Acids Res 2005, 33: 451-463.
31. Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. Embo J 2000, 19: 4439-4448.
32. Yuan Y, Compton SA, Sobczak K, Stenberg MG, Thornton CA, et al. Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res 2007, 35: 5474-5486.
33. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, et al. A muscleblind knockout model for myotonic dystrophy. Science 2003, 302: 1978-1980.
34. Kanadia RN, Shin J, Yuan Y, Beattie SG, Wheeler TM, et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A 2006, 103: 11748-11753.
35. Ho TH, Savkur RS, Poulos MG, Mancini MA, Swanson MS, et al. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J Cell Sci 2005, 118: 2923-2933.
36. Pascual M, Vicente M, Monferrer L, Artero R. The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing. Differentiation 2006, 74: 65-80.
37. Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet 2004, 13: 3079-3088.
38. Charlet BN, Savkur RS, Singh G, Philips AV, Grice EA, et al. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002, 10: 45-53.
39. Kino Y, Washizu C, Oma Y, Onishi H, Nezu Y, et al. MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1. Nucleic Acids Res 2009, 37: 6477-6490.
40. Dansithong W, Paul S, Comai L, Reddy S. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J Biol Chem 2005, 280: 5773-5780.
41. Savkur RS, Philips AV, Cooper TA, Dalton JC, Moseley ML, et al. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet 2004, 74: 1309-1313.
42. Ho TH, Charlet BN, Poulos MG, Singh G, Swanson MS, et al. Muscleblind proteins regulate alternative splicing. Embo J 2004, 23: 3103-3112.
43. Leroy O, Dhaenens CM, Schraen-Maschke S, Belarbi K, Delacourte A, et al. ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I. J Neurosci Res 2006, 84: 852-859.
44. Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 2006, 15: 2087-2097.
45. Ho TH, Bundman D, Armstrong DL, Cooper TA. Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum Mol Genet 2005, 14: 1539-1547.
46. Buj-Bello A, Furling D, Tronchere H, Laporte J, Lerouge T, et al. Muscle-specific alternative splicing of myotubularin-related 1 gene is impaired in DM1 muscle cells. Hum Mol Genet 2002, 11: 2297-2307.
47. 2+-ATPase in myotonic dystrophy type 1. Hum Mol Genet 2005, 14: 2189-2200.
48. Hino S, Kondo S, Sekiya H, Saito A, Kanemoto S, et al. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1. Hum Mol Genet 2007, 16: 2834-2843.
49. Wang GS, Kearney DL, De Biasi M, Taffet G, Cooper TA. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest 2007, 117: 2802-2811.
50. Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998, 280: 737-741.
51. Warf MB, Berglund JA. MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA substrate cardiac troponin T. RNA 2007, 13: 2238-2251.
52. Salvatori S, Furlan S, Fanin M, Picard A, Pastorello E, et al. Comparative transcriptional and biochemical studies in muscle of myotonic dystrophies (DM1 and DM2). Neurol Sci 2009, 30: 185-192.
53. Vihola A, Bachinski LL, Sirito M, Olufemi SE, Hajibashi S, et al. Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2 Acta Neuropathol 2010, 119: 465-479.
54. Timchenko LT, Miller JW, Timchenko NA, DeVore DR, Datar KV, et al. Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res 1996, 24: 4407-4414.
55. Kim DH, Langlois MA, Lee KB, Riggs AD, Puymirat J, et al. HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence. Nucleic Acids Res 2005, 33: 3866-3874.
56. Fardaei M, Larkin K, Brook JD, Hamshere MG. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res 2001, 29: 2766-2771.
57. Sofola OA, Jin P, Qin Y, Duan R, Liu H, et al. RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 2007, 55: 565-571.
58. Jin P, Duan R, Qurashi A, Qin Y, Tian D, et al. Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron 2007, 55: 556-564.
59. Ebralidze A, Wang Y, Petkova V, Ebralidse K, Junghans RP. RNA leaching of transcription factors disrupts transcription in myotonic dystrophy. Science 2004, 303: 383-387.
60. Salisbury E, Schoser B, Schneider-Gold C, Wang GL, Huichalaf C, et al. Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in myotonic dystrophy 2 patients. Am J Pathol 2009, 175: 748-762.
61. Chai Y, Koppenhafer SL, Shoesmith SJ, Perez MK, Paulson HL. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet 1999, 8: 673-682.
62. Peel AL, Rao RV, Cottrell BA, Hayden MR, Ellerby LM, et al. Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. Hum Mol Genet 2001, 10: 1531-1538.
63. Tian B, White RJ, Xia T, Welle S, Turner DH, et al. Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR. RNA 2000, 6: 79-87.
64. Malinina L. Possible involvement of the RNAi pathway in trinucleotide repeat expansion diseases. J Biomol Struct Dyn 2005, 23: 233-235.
65. Krol J, Fiszer A, Mykowska A, Sobczak K, de Mezer M, et al. Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol Cell 2007, 25: 575-586.
66. Osborne RJ, Lin X, Welle S, Sobczak K, O'Rourke JR, et al. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet 2009, 18: 1471-1481.
67. Risheg H, Graham JM Jr, Clark RD, Rogers RC, Opitz JM, et al. A recurrent mutation in MED12 leading to R961W causes Opitz-Kaveggia syndrome. Nat Genet 2007, 39: 451-453.
68. Kumari D, Usdin K. Chromatin remodeling in the noncoding repeat expansion diseases. J Biol Chem 2009, 284: 7413-7417.
69. Alwazzan M, Newman E, Hamshere MG, Brook JD. Myotonic dystrophy is associated with a reduced level of RNA from the DMWD allele adjacent to the expanded repeat. Hum Mol Genet 1999, 8: 1491-1497.
70. Gennarelli M, Pavoni M, Amicucci P, Angelini C, Menegazzo E, et al. Reduction of the DM-associated homeo domain protein (DMAHP) mRNA in different brain areas of myotonic dystrophy patients. Neuromuscul Disord 1999, 9: 215-219.
71. Frisch R, Singleton KR, Moses PA, Gonzalez IL, Carango P, et al. Effect of triplet repeat expansion on chromatin structure and expression of DMPK and neighboring genes, SIX5 and DMWD, in myotonic dystrophy. Mol Genet Metab 2001, 74: 281-291.
72. Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 2007, 28: 68-78.
73. Wang GS, Kuyumcu-Martinez MN, Sarma S, Mathur N, Wehrens XH, et al. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest 2009, 119: 3797-3806.
74. Hernandez-Hernandez O, Bermudez-de-Leon M, Gomez P, Velazquez-Bernardino P, Garcia-Sierra F, et al. Myotonic dystrophy expanded CUG repeats disturb the expression and phosphorylation of tau in PC12 cells. J Neurosci Res 2006, 84: 841-851.
75. Salisbury E, Sakai K, Schoser B, Huichalaf C, Schneider-Gold C, et al. Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1. Exp Cell Res 2008, 314: 2266-2278.
76. Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, et al. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem 2001, 276: 7820-7826.
77. Pelletier R, Hamel F, Beaulieu D, Patry L, Haineault C, et al. Absence of a differentiation defect in muscle satellite cells from DM2 patients. Neurobiol Dis 2009, 36: 181-190.
78. Ranum LP, Cooper TA. RNA-mediated neuromuscular disorders. Annu Rev Neurosci 2006, 29: 259-277.
79. Du H, Cline MS, Osborne RJ, Tuttle DL, Clark TA, et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy Nat Struct Mol Biol 2010, 17: 187-193.
80. Paillard L, Omilli F, Legagneux V, Bassez T, Maniey D, et al. EDEN and EDEN-BP, a cis element and an associated factor that mediate sequence-specific mRNA deadenylation in Xenopus embryos. Embo J 1998, 17: 278-287.
81. Moraes KC, Wilusz CJ, Wilusz J. CUG-BP binds to RNA substrates and recruits PARN deadenylase. RNA 2006, 12: 1084-1091.
82. Vlasova IA, Tahoe NM, Fan D, Larsson O, Rattenbacher B, et al. Conserved GU-rich elements mediate mRNA decay by binding to CUG-binding protein 1. Mol Cell 2008, 29: 263-270.
83. Zhang L, Lee JE, Wilusz J, Wilusz CJ. The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy. J Biol Chem 2008, 283: 22457-22463.
84. Mammarella A, Ferroni P, Paradiso M, Martini F, Paoletti V, et al. Tumor necrosis factor-alpha and myocardial function in patients with myotonic dystrophy type 1. J Neurol Sci 2002, 201: 59-64.
85. Iakova P, Wang GL, Timchenko L, Michalak M, Pereira-Smith OM, et al. Competition of CUGBP1 and calreticulin for the regulation of p21 translation determines cell fate. Embo J 2004, 23: 406-417.
86. Timchenko NA, Welm AL, Lu X, Timchenko LT. CUG repeat binding protein (CUGBP1) interacts with the 5' region of C/EBPbeta mRNA and regulates translation of C/EBPbeta isoforms. Nucleic Acids Res 1999, 27: 4517-4525.
87. Timchenko NA, Patel R, Iakova P, Cai ZJ, Quan L, et al. Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. J Biol Chem 2004, 279: 13129-13139.
88. Helbling-Leclerc A, Zhang X, Topaloglu H, Cruaud C, Tesson F, et al. et al. Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet 1995, 11: 216-218.
89. Camacho Vanegas O, Bertini E, Zhang RZ, Petrini S, Minosse C, et al. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci U S A 2001, 98: 7516-7521.
90. Matsumura K, Tome FM, Collin H, Azibi K, Chaouch M, et al. Deficiency of the 50K dystrophin-associated glycoprotein in severe childhood autosomal recessive muscular dystrophy. Nature 1992, 359: 320-322.
91. Kanagawa M, Toda T. The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis. J Hum Genet 2006, 51: 915-926.
92. Botta A, Rinaldi F, Catalli C, Vergani L, Bonifazi E, et al. The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients. J Med Genet 2008, 45: 639-646.
93. Jasinska A, Michlewski G, de Mezer M, Sobczak K, Kozlowski P, et al. Structures of trinucleotide repeats in human transcripts and their functional implications. Nucleic Acids Res 2003, 31: 5463-5468.
94. Ditch S, Sammarco MC, Banerjee A, Grabczyk E. Progressive GAA.TTC repeat expansion in human cell lines. PLoS Genet 2009, 5: e1000704.
95. Gomes-Pereira M, Fortune MT, Ingram L, McAbney JP, Monckton DG. Pms2 is a genetic enhancer of trinucleotide CAG.CTG repeat somatic mosaicism: implications for the mechanism of triplet repeat expansion.Hum Mol Genet 2004, 13: 1815-1825.
96. Matsuura T, Yamagata T, Burgess DL, Rasmussen A, Grewal RP, et al. Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet 2000, 26: 191-194.
97. Handa V, Yeh HJ, McPhie P, Usdin K. The AUUCU repeats responsible for spinocerebellar ataxia type 10 form unusual RNA hairpins. J Biol Chem 2005, 280: 29340-29345.
98. Lin X, Ashizawa T. Recent progress in spinocerebellar ataxia type-10 (SCA10). Cerebellum 2005, 4: 37-42.
99. Sobczak K, Krzyzosiak WJ. Patterns of CAG repeat interruptions in SCA1 and SCA2 genes in relation to repeat instability. Hum Mutat 2004, 24: 236-247.
100. Sobczak K, Krzyzosiak WJ. Imperfect CAG repeats form diverse structures in SCA1 transcripts. J Biol Chem 2004, 279: 41563-41572.
101. Margolis JM, Schoser BG, Moseley ML, Day JW, Ranum LP. DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum Mol Genet 2006, 15: 1808-1815.
102. Wakamiya M, Matsuura T, Liu Y, Schuster GC, Gao R, et al. The role of ataxin 10 in the pathogenesis of spinocerebellar ataxia type 10. Neurology 2006, 67: 607-613.
103. Bidichandani SI, Ashizawa T, Patel PI. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet 1998, 62: 111-121.
104. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000, 66: 6-15.
105. Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 1991, 252: 1097-1102.
106. Holt I, Mittal S, Furling D, Butler-Browne GS, Brook JD, et al. Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles. Genes Cells 2007, 12: 1035-1048.
107. Orengo JP, Chambon P, Metzger D, Mosier DR, Snipes GJ, et al. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A 2008, 105: 2646-2651.
108. Mankodi A, Logigian E, Callahan L, McClain C, White R, et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000, 289: 1769-1773.
109. Mahadevan MS, Yadava RS, Yu Q, Balijepalli S, Frenzel-McCardell CD, et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 2006, 38: 1066-1070.
110. Michlewski G, Krzyzosiak WJ. Pathogenesis of spinocerebellar ataxias viewed from the RNA perspective. Cerebellum 2005, 4: 19-24.
111. Botta A, Caldarola S, Vallo L, Bonifazi E, Fruci D, et al. Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2). Biochim Biophys Acta 2006, 1762: 329-334.
112. Mastroyiannopoulos NP, Feldman ML, Uney JB, Mahadevan MS, Phylactou LA. Woodchuck post-transcriptional element induces nuclear export of myotonic dystrophy 3' untranslated region transcripts. EMBO Rep 2005, 6: 458-463.
113. Dansithong W, Wolf CM, Sarkar P, Paul S, Chiang A, et al. Cytoplasmic CUG RNA foci are insufficient to elicit key DM1 features. PLoS ONE 2008, 3: e3968.
114. Mastroyiannopoulos NP, Chrysanthou E, Kyriakides TC, Uney JB, Mahadevan MS, et al. The effect of myotonic dystrophy transcript levels and location on muscle differentiation. Biochem Biophys Res Commun 2008, 377: 526-531.
115. Garcia-Lopez A, Monferrer L, Garcia-Alcover I, Vicente-Crespo M, Alvarez-Abril MC, et al. Genetic and chemical modifiers of a CUG toxicity model in Drosophila. PLoS ONE 2008, 3: e1595.
116. Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A 2009, 106: 13915-13920.
117. Furling D, Doucet G, Langlois MA, Timchenko L, Belanger E, et al. Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions. Gene Ther 2003, 10: 795-802.
118. Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A 2003, 100: 7195-7200.
119. Langlois MA, Lee NS, Rossi JJ, Puymirat J. Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol Ther 2003, 7: 670-680.
120. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A 2005, 102: 5820-5825.
121. Scholefield J, Greenberg LJ, Weinberg MS, Arbuthnot PB, Abdelgany A, et al. Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS ONE 2009, 4: e7232.
122. Yen L, Strittmatter SM, Kalb RG. Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA. Ann Neurol 1999, 46: 366-373.
123. Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009, 325: 336-339.
124. Warf MB, Nakamori M, Matthys CM, Thornton CA, Berglund JA. Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A 2009, 106: 18551-18556.
125. Arambula JF, Ramisetty SR, Baranger AM, Zimmerman SC. A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding. Proc Natl Acad Sci U S A 2009, 106: 16068-16073.
126. Pushechnikov A, Lee MM, Childs-Disney JL, Sobczak K, French JM, et al. Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc 2009, 131: 9767-9779.
127. Gareiss PC, Sobczak K, McNaughton BR, Palde PB, Thornton CA, et al. Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc 2008, 130: 16254-16261.
128. de Haro M, Al-Ramahi I, De Gouyon B, Ukani L, Rosa A, et al. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum Mol Genet 2006, 15: 2138-2145.
129. Wheeler TM, Lueck JD, Swanson MS, Dirksen RT, Thornton CA. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007, 117: 3952-3957.
130. Corbeil-Girard LP, Klein AF, Sasseville AM, Lavoie H, Dicaire MJ, et al. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions. Neurobiol Dis 2005, 18: 551-567.
131. Jung J, Xu K, Lessing D, Bonini NM. Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Hum Mol Genet 2009, 18: 4843-4852.
132. Branco J, Al-Ramahi I, Ukani L, Perez AM, Fernandez-Funez P, et al. Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases. Hum Mol Genet 2008, 17: 376-390.